Home › Companies › VKTX

Viking Therapeutics, Inc.

VKTX Rare disease Lead: Phase 3 5 Biotech Distilled articles ↓

GI/Hepatology Metabolic Neurology Peptide Small Molecule

Most recent annual filing: 2026-02-11

Pipeline (9 active programs)

VK2735

Peptide Target: GLP-1 receptor, GIP receptor, GLP-1R, GIPR

Obesity Phase 3 subcutaneous
Type 2 Diabetes Phase 3 subcutaneous
Obesity Phase 2 oral

VK2809

Small Molecule Target: thyroid hormone receptor beta, TR-Beta

VK0214

Small Molecule Target: thyroid hormone receptor beta, TR-Beta

X-Linked Adrenoleukodystrophy Phase 1 oral

VK5211

Small Molecule Target: androgen receptor

Hip Fracture Phase 2 oral
Undisclosed indication Phase 2

VK0612

Undisclosed indication Phase 2

Biotech Distilled coverage (5)

2026-05-01 UPDATE: Viking Therapeutics (VKTX) - Ligand Pulls the Pin on VK2809 🔒 Paid
2026-04-30 UPDATE: Viking Therapeutics (VKTX) - The Burn Rate Catches Up 🔒 Paid
2026-02-11 Update: Viking Therapeutics (VKTX) – The "Wait and Bleed" Quarter 🔒 Paid
2026-01-10 Update: Viking Therapeutics (VKTX) – Commercial Bluff or Go It Alone Suicide Pact? 🔒 Paid
2025-12-23 Viking Therapeutics (VKTX): Scientific Due Diligence for Lead and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.